Singapore markets closed

CTI BioPharma Corp. (CTIC)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
5.79+0.08 (+1.40%)
At close: 04:00PM EDT
5.82 +0.03 (+0.52%)
After hours: 07:44PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.71
Bid5.78 x 3000
Ask5.86 x 800
Day's range5.63 - 5.92
52-week range1.43 - 7.80
Avg. volume4,923,851
Market cap662.289M
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-1.23
Earnings date10 Nov 2022 - 14 Nov 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est10.41
  • Motley Fool

    Why CTI BioPharma Stock Got Rocked on Tuesday

    A big revenue beat couldn't make up for a modest bottom-line miss on Tuesday for CTI BioPharma (NASDAQ: CTIC). This is CTI's drug that was approved by the Food and Drug Administration (FDA) in March for the treatment of myelofibrosis, a rare bone marrow disorder.

  • Zacks

    CTI BioPharma (CTIC) Reports Q2 Loss, Tops Revenue Estimates

    CTI BioPharma (CTIC) delivered earnings and revenue surprises of -5% and 20.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    Why CTI BioPharma Stock Blasted 18% Higher Today

    The stock of CTI BioPharma (NASDAQ: CTIC) was an outlier in the biotech sector on Thursday, and in the best way possible. The company's shares surged more than 18% higher on the day, following a new and bullish analyst note on the company based on positive anecdotal evidence. Peaker rates it an unequivocal outperform (read: buy), at a price target of $10 per share.